Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 998-1004

  Negaard, Helene F S ^a,b   Svennevig, Katja ^c   Kolset, Svein Olav ^c   Iversen, Nina ^a   Lothe, Inger Marie Bowitz ^a   Østenstad, Bjørn ^a   Sandset, Per Morten ^a,b   Iversen, Per Ole ^a,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Angiogenesis; Extracellular matrix; Metalloproteinases; Non Hodgkin lymphoma; Syndecan 1

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIBODY; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; MESSENGER RNA; SYNDECAN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; MALE; MONONUCLEAR CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; UPREGULATION;

EID: 68449103587     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902889270     Document Type: Article

References (35)

1. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227-244.
2. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-285.
3. Dean RA, Butler GS, Hamma-Kourbali Y, Delbe J, Brigstock DR, Courty J, et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and vegf/connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol 2007;27:8454-8465.
4. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25:99-113.
5. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989;1:27-35.
6. Sanderson RD, Borset M. Syndecan-1 in B lymphoid malignancies. Ann Hematol 2002;81:125-135.
7. Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellén L, et al. Heparan sulfate in trans potentiates VEGFRmediated angiogenesis. Dev Cell 2006;10:625-634.
8. Filla MS, Dam P, Rapraeger AC. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol 1998;174:310-321.
9. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 2001;14:1052-1058.
10. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1998;18: 40-46.
11. Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, et al. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer 1998;76: 749-756.
12. Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004;103:1069-1077.
13. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 2007;27:310-316.
14. Hazar B, Polat G, Seyrek E, Bagdatoglglu O, Kanik A, Tiftik N. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma. Int J Clin Pract 2004;58:139-143.
15. Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. Eur J Haematol 2008;80:46-54.
16. Negaard HFS, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Østenstad B, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009;23:162-169.
17. Constantinescu CS, Grygar C, Kappos L, Leppert D. Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. Cytokine 2001; 13:244-247.
18. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996;156:3952-3960.
19. Negaard HFS, Iversen PO, Ostenstad B, Iversen N, Holme PA, Sandset PM. Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. Thromb Haemost 2008;99:1040-1048.
20. WHO. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon: IARC Press; 2001.
21. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
22. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
23. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
24. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996;74:1161-1167.
25. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998;83: 832-840.
26. McCawley LJ, Matrisian LM. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 2000;6:149-156.
27. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17: 463-516.
28. Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998;75:81-87.
29. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, et al. Matrix metalloproteinases generate angiostatin: Effects on neovascularization. J Immunol 1998;161:6845-6852.
30. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J-M. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-251.
31. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, et al. Physiological levels of tumstatin, a fragment of collagen IV [alpha]3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via [alpha]V[beta]3 integrin. Cancer Cell 2003;3:589-601.
32. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ESJM. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g., acute leukemia. Crit Rev Oncol Hematol 2004;50:87-100.
33. Negaard H, Dahm A, Sandset PM, Iversen PO, Ostenstad B. Angiogenesis and hemostasis in hematological neoplasias. Curr Drug Targets 2005;6:683-699.
34. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-893.
35. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005;344:147-149.